Comparative Pharmacology
Head-to-head clinical analysis: MARAVIROC versus SELZENTRY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MARAVIROC versus SELZENTRY.
MARAVIROC vs SELZENTRY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective, reversible, small-molecule antagonist of the chemokine receptor CCR5, preventing HIV-1 entry into CD4+ T cells by blocking gp120-CCR5 interaction.
Selective CCR5 receptor antagonist; blocks HIV-1 entry by binding to the chemokine receptor CCR5 on CD4+ T cells, preventing viral gp120 from interacting with the receptor.
300 mg orally twice daily
150 mg orally twice daily, 300 mg orally twice daily, or 600 mg orally twice daily depending on concomitant medications; must be adjusted for CYP3A inducers or inhibitors.
None Documented
None Documented
Terminal elimination half-life is 14-18 hours following oral administration, allowing for twice-daily dosing.
Clinical Note
moderateMaraviroc + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Maraviroc."
Clinical Note
moderateMaraviroc + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Maraviroc."
Clinical Note
moderateMaraviroc + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Maraviroc."
Clinical Note
moderateMaraviroc + Fluconazole
Terminal elimination half-life is approximately 2-3 hours (single dose), but due to irreversible binding to CCR5, pharmacodynamic half-life is 2-4 days. Clinical context: Twice-daily dosing maintains CCR5 blockade.
Renal excretion accounts for approximately 20% of the dose as unchanged drug; fecal elimination accounts for about 76% (mainly as metabolites).
Primarily hepatobiliary and fecal: ~76% of dose recovered in feces as parent drug and metabolites; renal elimination minor (~8-10% of dose in urine, mostly as metabolites).
Category A/B
Category C
CCR5 Antagonist
CCR5 Antagonist
"The metabolism of Fluconazole can be decreased when combined with Maraviroc."